NUFORMIX PLC LS -001
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more
Market Cap & Net Worth: NUFORMIX PLC LS -001 (1RT)
NUFORMIX PLC LS -001 (F:1RT) has a market capitalization of $2.17 Million (€2.11 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #34363 globally and #3946 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NUFORMIX PLC LS -001's stock price €0.00 by its total outstanding shares 2109749903 (2.11 Billion).
NUFORMIX PLC LS -001 Market Cap History: 2021 to 2026
NUFORMIX PLC LS -001's market capitalization history from 2021 to 2026. Data shows growth from $17.32 Million to $2.17 Million (0.00% CAGR).
NUFORMIX PLC LS -001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NUFORMIX PLC LS -001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1RT by Market Capitalization
Companies near NUFORMIX PLC LS -001 in the global market cap rankings as of March 19, 2026.
Key companies related to NUFORMIX PLC LS -001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NUFORMIX PLC LS -001 Historical Marketcap From 2021 to 2026
Between 2021 and today, NUFORMIX PLC LS -001's market cap moved from $17.32 Million to $ 2.17 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.17 Million | 0.00% |
| 2025 | €2.17 Million | +100.00% |
| 2024 | €1.08 Million | -50.00% |
| 2023 | €2.17 Million | +100.00% |
| 2022 | €1.08 Million | -93.75% |
| 2021 | €17.32 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NUFORMIX PLC LS -001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.17 Million USD |
| MoneyControl | $2.17 Million USD |
| MarketWatch | $2.17 Million USD |
| marketcap.company | $2.17 Million USD |
| Reuters | $2.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.